How much does a box of Revumenib currently cost?

Revumenib (Revumenib) is a targeted therapy drug, mainly used to treat patients with KMT2A (formerly MLL) gene mutation It is especially suitable for some patients with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). The drug was developed by Syndax and was approved by the U.S. FDA2024 n> was approved for marketing under the trade name Revuforj, marking a key step in the treatment of leukemia by targeting the Menin-MLL pathway.

As for drug prices, currentlyRevumenib is priced relatively high in the US market. According to public information, the drug is priced at approximately 39,500 US dollars per month, which is equivalent to approximately 28 yuan in RMB. This price is for one treatment cycle (one month) for a standard adult patient and covers the standard daily oral dose. Since the drug is a new orphan drug and its targeting mechanism is relatively advanced, the price is set at a high-end level and it has not yet entered the medical insurance system, posing a heavy financial burden.

In addition to the officially marketed clinical drugs, there are also Revumenib available on the market for scientific research purposes, such as purified versions of the compound for laboratory research. The packaging specifications of such products are generally 25mg, 50mg or 100mg, with prices ranging from 450 to 2700 US dollars respectively. This type of drug is not used for clinical treatment, but is for experimental research purposes only and cannot be used as a substitute for patient medication. Therefore, when purchasing drugs, special attention must be paid to the distinction between source and purpose to avoid mistakenly purchasing research-grade products.

As of2025, Revimenib is still only available in some regions such as the United States. It has not yet been approved for use in mainland China, and domestic patients cannot purchase it directly. If you need to use this medicine, you can only obtain it through overseas medical channels. Considering its significant efficacy and highly targeted targeting mechanism, if it can be included in medical insurance or a generic version is launched in the future, it is expected to greatly alleviate the economic pressure caused by high drug prices and bring practical treatment options to more leukemia patients.

Reference materials:https://www.drugs.com/